Foundation Medicine Inc (NASDAQ:FMI) CFO Jason Ryan sold 12,500 shares of the stock in a transaction on Thursday, March 16th. The stock was sold at an average price of $31.68, for a total transaction of $396,000.00. Following the sale, the chief financial officer now directly owns 56,230 shares in the company, valued at $1,781,366.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Jason Ryan also recently made the following trade(s):
- On Friday, January 13th, Jason Ryan sold 1,777 shares of Foundation Medicine stock. The stock was sold at an average price of $19.00, for a total transaction of $33,763.00.
- On Wednesday, January 4th, Jason Ryan sold 4,665 shares of Foundation Medicine stock. The stock was sold at an average price of $17.74, for a total transaction of $82,757.10.
Shares of Foundation Medicine Inc (NASDAQ:FMI) remained flat at $32.45 during mid-day trading on Monday. The company’s stock had a trading volume of 171,923 shares. The stock has a 50 day moving average price of $25.80 and a 200 day moving average price of $22.43. Foundation Medicine Inc has a one year low of $15.10 and a one year high of $35.30. The company’s market capitalization is $1.15 billion.
Foundation Medicine (NASDAQ:FMI) last announced its quarterly earnings data on Wednesday, February 22nd. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by $0.06. The company earned $28.80 million during the quarter, compared to analyst estimates of $29.23 million. Foundation Medicine had a negative return on equity of 42.21% and a negative net margin of 84.67%. The company’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.55) EPS. On average, equities research analysts expect that Foundation Medicine Inc will post ($3.95) EPS for the current fiscal year.
Your IP Address:
A number of brokerages have weighed in on FMI. Janney Montgomery Scott raised shares of Foundation Medicine from a “sell” rating to a “neutral” rating and set a $31.00 target price on the stock in a report on Tuesday, March 7th. Zacks Investment Research cut shares of Foundation Medicine from a “buy” rating to a “hold” rating in a report on Wednesday, January 4th. Six analysts have rated the stock with a hold rating, Foundation Medicine presently has a consensus rating of “Hold” and a consensus target price of $27.33.
Several large investors have recently made changes to their positions in the company. Discovery Group I LLC increased its stake in shares of Foundation Medicine by 2.3% in the fourth quarter. Discovery Group I LLC now owns 1,596,818 shares of the company’s stock valued at $28,264,000 after buying an additional 36,204 shares during the last quarter. Oppenheimer & Co. Inc. boosted its position in shares of Foundation Medicine by 7.0% in the third quarter. Oppenheimer & Co. Inc. now owns 721,271 shares of the company’s stock valued at $16,842,000 after buying an additional 47,350 shares during the period. ARK Investment Management LLC purchased a new position in shares of Foundation Medicine during the fourth quarter valued at approximately $5,276,000. State Street Corp boosted its position in shares of Foundation Medicine by 6.2% in the fourth quarter. State Street Corp now owns 221,817 shares of the company’s stock valued at $3,926,000 after buying an additional 12,872 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Foundation Medicine by 0.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 122,863 shares of the company’s stock valued at $2,869,000 after buying an additional 599 shares during the period. Institutional investors and hedge funds own 31.44% of the company’s stock.
Foundation Medicine Company Profile
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. The Company’s segment is the business of delivering molecular information about cancer to its customers. Its products provide genomic information about each patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies.
Receive News & Ratings for Foundation Medicine Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine Inc and related companies with MarketBeat.com's FREE daily email newsletter.